New 6-year data for Roche ’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis

             Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS ® (ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of OCREVUS, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurolog y (AAN) Annual Meeting and will be made available online via virtual presentation in the coming weeks (in lieu of an in-person event).“For people with MS, maintaining mobility for as long as possible is very important. We are encouraged by these new longer-term analyses showing that earlier initiation of OCREVUS treatment may reduce the risk of needing a walking aid by nearly 50 percent over six years,” said Levi Garraway, M.D ., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “Slowing MS progression earlier in the disease course – not just treating relapses – may bring additional clinically meaningful outcomes to people living with this disease.”Effect of OCREVUS on disability progression and risk of needing a walking aid in patients with RMS Earlier treatment with OCREVUS may delay the risk of needing a walking aid compared to those who switched from interferon beta-1a two years later in a new post-hoc analysis from the open-...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news